Taurine 11 pp 543-553 | Cite as

Targeting Taurine Transporter (TauT) for Cancer Immunotherapy of p53 Mutation Mediated Cancers – Molecular Basis and Preclinical Implication

  • Xiaobin HanEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1155)


Taurine transporter (TauT) has been identified as a target gene of p53 tumor suppressor. TauT is also found to be overexpressed in variety type of human cancers, such as leukemia. This study showed that expression of TauT was upregulated by c-Myc and c-Jun oncogenes. To explore whether blocking of TauT inhibits tumor development, the RNA interference (RNAi) and immune targeting approaches were tested in tumor cells in vitro and in p53 mutant mice in vivo. Knockdown of TauT expression by RNAi resulted in cell cycle G2 arrest and suppressed human breast cancer MCF-7 cells proliferation determined by colonies production and cell migration assays. Knockdown of TauT also rendered MCF-7 cells more susceptible to chemotherapeutic drug-induced apoptosis. An antibody specifically against TauT blocked taurine uptake and induced cell cycle G2 arrest leading to cell death of variety type of tumor cells without affecting the viability of normal mammalian cells. TauT peptide vaccination significantly increased median lifespan (1.5-fold) of the p53 null mice and rescued p53+/− mice by extending the median lifespan from 315 days to 621 days. Furthermore, single dose treatment of tumor-bearing (thymic lymphoma) p53 null mice with TauT peptide reduced tumor size by about 50% and significantly prolonged survival of these mice from average 7 days (after observing the thymic lymphoma) to 21 days. This finding demonstrates that a novel TauT peptide vaccine can delay, inhibit, and/or treat p53 mutation related spontaneous tumorigenesis in vivo. Therefore, TauT peptide may be used as a universal cancer vaccine to prevent and/or treat patients with p53 mutation-mediated cancers.


TauT TauT peptide Cancer immunotherapy p53 



p53 tumor suppressor gene


RNA interference


taurine transporter


  1. Boucrot E, Kirchhausen T (2008) Mammalian cells change volume during mitosis. PLoS One 3(1):e1477CrossRefGoogle Scholar
  2. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366):215–221CrossRefGoogle Scholar
  3. Han X, Chesney RW (2003) Regulation of taurine transporter gene (TauT) by WT1. FEBS Lett 540(1–3):71–76CrossRefGoogle Scholar
  4. Han X, Chesney RW (2009) Mechanism of TauT in protecting against cisplatin-induced kidney injury (AKI). Adv Exp Med Biol 643:105–112CrossRefGoogle Scholar
  5. Han X, Chesney RW (2013) Knockdown of TauT expression impairs human embryonic kidney 293 cell development. Adv Exp Med Biol 776:307–320CrossRefGoogle Scholar
  6. Han X, Budreau AM, Chesney RW (1996) Role of conserved peptide in taurine transporter inactivation modulated by protein kinase C. J Am Soc Nephrol 7(10):2088–2096PubMedGoogle Scholar
  7. Han X, Budreau AM, Chesney RW (1997a) Adaptive regulation of MDCK cell taurine transporter (pNCT) mRNA: transcription of pNCT gene is regulated by external taurine concentration. Biochim Biophys Acta 1351(3):296–304CrossRefGoogle Scholar
  8. Han X, Budreau AM, Chesney RW (1997b) Functional expression of rat renal cortex taurine transporter in Xenopus laevis oocytes: adaptive regulation by dietary manipulation. Pediatr Res 41(5):624–631CrossRefGoogle Scholar
  9. Han X, Budreau AM, Chesney RW (1999) Ser-322 is a critical site for PKC regulation of the MDCK cell taurine transporter (pNCT). J Am Soc Nephrol 10(9):1874–1879PubMedGoogle Scholar
  10. Han X, Budreau AM, Chesney RW (2000a) Cloning and characterization of the promoter region of the rat taurine transporter (TauT) gene. Adv Exp Med Biol 483:97–108CrossRefGoogle Scholar
  11. Han X, Budreau AM, Chesney RW (2000b) Identification of promoter elements involved in adaptive regulation of the taurine transporter gene: role of cytosolic Ca2+ signaling. Adv Exp Med Biol 483:535–544CrossRefGoogle Scholar
  12. Han X, Patters AB, Chesney RW (2002) Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells. J Biol Chem 277(42):39266–39273CrossRefGoogle Scholar
  13. Han X, Patters AB, Jones DP, Zelikovic I, Chesney RW (2006) The taurine transporter: mechanisms of regulation. Acta Physiol (Oxf) 187(1–2):61–73CrossRefGoogle Scholar
  14. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA (1993) Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7(10):938–943CrossRefGoogle Scholar
  15. Hoffman B, Olson JE, Kreisman N (2000) The role of taurine for cellular volume regulation of the hippocampus. Acad Emerg Med 7(10):1168PubMedGoogle Scholar
  16. Hursting SD, Perkins SN, Phang JM (1994) Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 91(15):7036–7040CrossRefGoogle Scholar
  17. Ito T, Fujio Y, Hirata M, Takatani T, Matsuda T, Muraoka S, Takahashi K, Azuma J (2004) Expression of taurine transporter is regulated through the TonE (tonicity-responsive element)/TonEBP (TonE-binding protein) pathway and contributes to cytoprotection in HepG2 cells. Biochem J 382(Pt 1):177–182CrossRefGoogle Scholar
  18. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV (2012) Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice. Aging (Albany NY) 4(10):709–714CrossRefGoogle Scholar
  19. Lambert IH (2004) Regulation of the cellular content of the organic osmolyte taurine in mammalian cells. Neurochem Res 29(1):27–63CrossRefGoogle Scholar
  20. Learn DB, Fried VA, Thomas EL (1990) Taurine and hypotaurine content of human leukocytes. J Leukoc Biol 48(2):174–182CrossRefGoogle Scholar
  21. Olson JE, Kreisman NR, Lim J, Hoffman-Kuczynski B, Schelble D, Leasure J (2003) Taurine and cellular volume regulation in the hippocampus. Adv Exp Med Biol 526:107–114CrossRefGoogle Scholar
  22. Plosker GL (2011) Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs 71(1):101–108CrossRefGoogle Scholar
  23. Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R (2018) Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med 10(426)CrossRefGoogle Scholar
  24. Witjes JA (2007) What is the optimal BCG dose in non-muscle-invasive bladder cancer? Eur Urol 52(5):1300–1302CrossRefGoogle Scholar
  25. Wittet S, Tsu V (2008) Cervical cancer prevention and the Millennium Development Goals. Bull World Health Organ 86(6):488–490CrossRefGoogle Scholar
  26. Yasunaga M, Matsumura Y (2014) Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. Sci Rep 4:4852CrossRefGoogle Scholar
  27. Zlotek-Zlotkiewicz E, Monnier S, Cappello G, Le Berre M, Piel M (2015) Optical volume and mass measurements show that mammalian cells swell during mitosis. J Cell Biol 211(4):765–774CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations